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1875-9572/Copyrightª 2014, Taiwan P
NC-ND license (http://creativecommoMaple syrup urine disease (MSUD) is an autosomal recessive aminoacidopathy secondary to an
enzyme defect in the catabolic pathway of the branched-chain amino acids (BCAAs: leucine,
isoleucine, and valine). Accumulation of their corresponding keto-acids leads to encephalop-
athy if not treated in time. A newborn male patient was suspected to have MSUD after tandem
mass study when he presented symptoms and signs suggestive neonatal sepsis, anemia, and
diarrhea. Food restriction of BCAAs was started; however, acrodermatitis enteropathica-like
skin eruptions occurred at age 2 months. The skin rashes resolved after adding BCAAs and ad-
justing the infant formula. At age 7 months, he suffered from recurrent skin lesions, zinc defi-
ciency, osteoporosis, and kyphosis of the thoracic spine with acute angulation over the T11-T12
level associated with spinal compression and myelopathy. After supplementation of zinc prod-
ucts and pamidronate, skin lesions and osteopenia improved gradually. Direct sequencing of
the DBT gene showed a compound heterozygous mutation [4.7 kb deletion and c.650-
651insT (L217F or L217fsX223)]. It is unusual that neurodegeneration still developed in this pa-
tient despite diet restriction. Additionally, brain and spinal magnetic resonance imaging, bone
mineral density study, and monitoring of zinc status are suggested in MSUD patients.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Maple syrup urine disease (MSUD, OMIM 248600) derives its
name from the odor of the patient’s urine, which resembles
that of maple syrup (burned sugar). MSUD has been
described in all ethnic groups and occurs in about
1/185,000 and 1/101,624 newborns in the USA and Taiwan,General Hospital, 280, Section 4,
.
013.10.013
ediatric Association. Published by
ns.org/licenses/by-nc-nd/4.0/).respectively.1,2 MSUD is caused by the deficiency of a
branched-chain a-keto acid dehydrogenase (BCKD) com-
plex, which catalyzes the oxidative decarboxylation of the
a-keto acids of branched-chain amino acids (BCAAs:
leucine, isoleucine, and valine).1,2 Accumulation of the
pathogenic compounds including BCAAs and their corre-
sponding a-keto acids contribute to the phenotype ofJen-Ai Road, Taipei 10630, Taiwan.
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encoding for the BCKD components [BCKDHA (accession
number: HS11695), BCKDHB (HS11696), and DBT (HS11697)]
may be responsible for this disease.1,2 All patients with
MSUD are at an increased risk of developing decompensat-
ing status of metabolism during periods of increased protein
catabolism (e.g., concomitant illness, trauma, and sur-
gery).1 With early diagnosis, as well as appropriate treat-
ment at the time of diagnosis and during episodes of
potential metabolic decompensation, the deterioration and
comorbidity can almost always be prevented.1e4 The re-
ported male infant suffered from early onset of acro-
dermatitis enteropathica (AE)-like skin lesions secondary to
isoleucine deficiency. However, recurrent skin lesions, zinc
deficiency, significant osteoporosis, kyphoscoliosis with
spinal compression, and myelopathy developed at age 7
months despite adequate diet control for BCAAs. DNA
studies on the BCKDHA, BCKDHB, and DBT genes were
performed.Figure 1 Spinal X-ray study showing kyphosis of the T-L spine
with acute angulation at T11-12 level.2. Case report
This male patient is the second child of young, healthy, and
nonconsanguineous parents of the Amis Tribe (Aborigines in
Taiwan). He was born full-term with birth weight of 3275 g,
birth length of 51 cm, head circumference of 33.5 cm, after
a smooth pregnancy course and vaginal delivery. Decreased
appetite and activity with easy choking developed since the
7th day after birth, accompanied by dry lips, hypothermia,
and constipation. He was treated as neonatal sepsis, but
subsequent features including bulging fontanelle, twitching
of limbs, and apparent body odor were noted. Anemia with
hemoglobin 1.36 mM [reference range (rr), 1.40e2.17mM]
and thrombocytosis (613  109 platelets/L; rr,
150e400  109 platelets/L), slightly elevated liver en-
zymes, and hypoglycemia (glucose: 2.16 mM; rr,
3.3e5.5 mM) were found. A diagnosis of MSUD was made
based on the clinical features, and findings of tandem mass
metabolic screening in dried blood spots: high levels of
valine (1026mM; rr, 84.07e354mM) and leucine/isoleucine
(829.41mM; rr, 56.82e287mM). Later plasma BCAAs concen-
trations detected by an amino acid analyzer showed valine
1350 mM (rr, 86e190mM), leucine 3105 mM (rr, 48e160mM),
isoleucine 543 mM (rr, 26e91mM), and urine gas chroma-
tography/mass spectrometry studies revealed elevated a-
hydroxyisovalerate, 2-hydroxyisovaleric, 3-hydroxyvaleric,
2-hydroxy-3-methylvaterate, lactate, pyruvate, and a-
ketoglutarate. Seven days after initiating therapy with a
particular diet (14% MJ MSUD Diet Powder, from Mead
Johnson & Company, Evansville, IN, US; total protein: 2.4 g/
kg/day, along with 62.5 mg/kg/day leucine), the plasma
leucine/isoleucine and valine concentrations were reduced
to about 1.25e1.5 times the upper normal limits. In addi-
tion, administering thiamine (10e20 mg/day) for 3 weeks
excluded the possibility of thiamine-responsive MSUD. At
age 1.5 months, hypertonicity of the lower extremities
developed. Brain ultrasound showed abnormal faint echo-
genicity over the bilateral hemispheres, favoring edema or
infarction. The result of echocardiography, thyroid, kidney,
and liver function tests were all normal. At age 2 months,
progressive scaling over the face, trunk, limbs, perineum,scalp, and digits appeared together with anemia and diar-
rhea. His periorificial and acral dermatitis was resistant to
topical corticosteroid therapy. Plasma BCAAs concentra-
tions at the time were as follows: valine 71 mM, leucine
50 mM, and isoleucine 15.7 mM. Serum zinc concentration
was slightly decreased (zinc: 128.8 mM; rr, 144e227 mM).
AE-like syndrome secondary to isoleucine and valine defi-
ciency was suspected, possibly due to over-restriction of
protein intake. Subsequent supplementation of BCAAs
(115 mg/kg/day of leucine, 90 mg/kg/day of isoleucine,
and 100 mg/kg/day of valine, combined with other amino
acids) resulted in a rapid amelioration of his skin eruption.
Later plasma concentrations of BCAAs (measured every 2e3
months) were kept at about twice (1.2e2.9) of mean levels
of normal ranges by adjusting the milk formula.
At age 5 months, electroencephalography showed
diffuse cortical dysfunction and focal epileptiform
discharge. Motor development was markedly retarded.
Recurrent skin rashes as AE and scoliosis were noted at age
7 months. Plasma zinc concentration was markedly
decreased (92.6 mM). Imaging studies showed kyphoscoliosis
of the thoraco-lumbar spine with acute angulation at the
T11-12 level (Figure 1). Wedging deformity of the T11 and
T12 vertebrae with retropulsion of the posterior bony
margins compressing the lower spinal cord and conus
medullaries resulted in hyperintensity and swelling on
Maple syrup urine disease 433spinal magnetic resonance imaging, suggestive of spinal
cord edema (Figure 2). Magnetic resonance imaging of the
brain showed enlargement of the left hemisphere with
asymmetry, prominent cisterns, and sulci of bilateral
hemispheres, and signal changes of bilateral globus pal-
lidus, cerebral peduncle, tectum, and periphery of pons.
Bone mineral densitometry showed osteopenia (0.184 g/
cm2, Z-score: e5.6). Serum calcium, phosphate, thyroid,
and parathyroid hormone levels were all within normal
ranges. His skin lesions resolved 2 weeks after supplemen-
tation with zinc gluconate (35 mg/day). DNA studies over
the DBT (dihydrolipoamide branched chain transacylase E2)
gene by direct sequencing and duplex PCR showed a com-
pound heterozygous mutation. A nucleotide T was inserted
between nucleotides 650 and 651 in exon 6, leading to a
frameshift causing a translational stop seven codons
downstream in addition to a 4.7 kb deletion [4.7 kb deletion
and c.650-651insT (L217F or L217fsX223); Figure 3].
At age 2 years, his height and weight were 80 cm (5th
percentile) and 10.5 kg (7th percentile), respectively. He
still suffered from recurrent respiratory and urinary tract
infection. Moderate psychomotor retardation was noted.
The electroencephalography recordings turned negative.
Recent laboratory findings showed that both anemia and Zn
deficiency were corrected. His bone mineral density wasFigure 2 Magnetic resonance imaging study of the spine
showing compression over the lower spinal cord and conus
medullaris resulting in cord edema.improved (0.378 g/cm2, Z: e1.8) after intravenous
pamidronate disodium with a dosage of 15 mg/m2 for 4
hours every month for 2.1 years.3. Discussion
MSUD is an inherited disorder caused by defects of the
branched-chain a-keto acid dehydrogenase complex.
Accumulation of leucine in particular causes neurological
symptoms, whereas elevation of plasma isoleucine is asso-
ciated with the maple syrup odor.1,3 Classic MSUD is the
most common form of MSUD, with symptoms developing in
neonates aged 4e7 days when they are dependent on the
feeding regimen.1,3,4 The initial symptoms typically include
poor feeding, vomiting, poor weight gain, and increasing
lethargy. Untreated patients often show significant devel-
opmental delays earlier with alternating muscular hypoto-
nia or hypertonia, dystonia, seizures, and encephalopathy
and may die within the first months of life.1,3e5
Associated AE-like syndrome has been reported in MSUD
patients during therapeutic protein restriction diet treat-
ment.1,6 Iatrogenic isoleucine deficiency is an important
etiology because it is essential for normal growth and dif-
ferentiation of keratinocytes.6,7 The first episode of AE-like
skin manifestations and diarrhea in the present patient was
due to amino acids restrictions. Supplementation of the
diet with BCAAs (especially isoleucine) may lead to a
prompt improvement of the skin lesions. The second onset
of AE-like eruptions may have been a result of a zinc defi-
ciency, and a rapid and positive clinical response was
demonstrated after zinc supplementation. Clinical pictures
resembling AE have been described in acquired zinc defi-
ciency and deficiencies of other nutrients such as biotin,
essential fatty acids and amino acids after being fed a low-
protein diet limited in branched-chain amino acids in
organic acidosis as well as biotin metabolism disorders.6
Thus, the dietary deficiencies associated with the treat-
ment of organic aciduria such as MSUD should be added to
the causes of AE-like cutaneous lesions.6,7
Early diagnosis and dietary intervention by restricting
intake of BCAAs, as well as exogenous toxin removal, will
prevent complications and may allow normal intellectual
development.1,4,8 However, in addition to skin eruptions
caused by isoleucine or zinc deficiency, treated patients
often present various degrees of psychomotor delay/
mental retardation.1,9 Leukodystrophies can occur in ge-
netic metabolic diseases such as MSUD, possibly resulting
from biochemical abnormalities which interfere with the
normal build-up and/or maintenance of myelin leading to
hypo- (or arrested) myelination, myelin edema, or dys-
myelination with resultant demyelination.10,11 High-grade
edema and leukodystrophy with brainstem and spinal cord
involvement and high lactate detected by diffusion-
weighted magnetic resonance imaging have been found in
MSUD.10,11 Zinc is an essential trace element that is incor-
porated into a number of human metalloproteins (zinc-
metalloproteins). The activity of superoxide dismutase,
which removes the anion superoxide by accelerating the
rate of its dismutation to hydrogen peroxide, is considered
to be correlated with zinc levels.5 The antioxidant activity
provided by superoxide dismutase may be decrease in the
Figure 3 DNA studies show a compound heterozygous mutation over the DBT gene: (A) Identification of the heterozygous 4.7 kb
deletion by duplex PCR: The 244-bp band is generated by primer sets Ex11F-Ex11B and the 750-bp fragment is generated by Ex11F-
ExdelB in normal control. The 388-bp duplex PCR product is produced by primer sets DelF-DelB in the patient. The presence of all
three bands represents a heterozygous deletion carrier, and (B) a nucleotide T is inserted between nucleotides 650 and 651, leading
to a frame shift causing a translational stop seven codons downstream: c.650-651insT (L217F or L217fsX223). A 100-bp DNA ladder is
used as a marker.
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tive stress may contribute to the development of myelop-
athy and osteoporosis, which may lead to kyphoscoliosis in
MSUD patients.5,10,12 The increased lipid peroxidation and
decreased antioxidant reactivity in plasma of MSUD pa-
tients will lead to cytotoxic edema and damaged
oligodendro-axonal units within the affected white matter
and spinal cord.10,11 The patient has normal calcium phos-
phate status and parathyroid function. Other factors, such
as profoundly diminished physical activity level, and
nutritional deficiency such as fat and fat-soluble vitamin D
or E may contribute to his spinal lesions. The causes of zinc
deficiency in MSUD patients may be secondary to a protein
restricted diet that contains a lower amount of dietary
zinc, decreased intake, low zinc stores, or increased uri-
nary zinc excretion. Therefore, it is proposed that dietary
zinc supplementation (4.6 mg/kg/day) should be incorpo-
rated as an adjuvant therapy in MSUD.7
MSUD is predominantly caused by mutations in the
BCKDHA, BCKDHB, and DBT genes, which encode for the
E1a, E1b, and E2 subunits of the human mitochondrial BCKD
complex.13,14 No good genotypeephenotype correlation
between molecular and clinical phenotypes exists.13,14 This
patient is compound heterozygous for two different muta-
tions affecting the E2 gene including a large deletion
(4.7 kb) mutation caused by a nonhomologous recombina-
tion of the long interspersed nuclear elements 1 (LINE-1) in
intron 10 and the Alu in the 30 UTR of the E2 gene, which is
commonly seen in classic MSUD patients of the Austronesian
aboriginal tribe Paiwan in Taiwan.15 As the 11 Taiwanese
Austronesian aboriginal tribes share a common origin, this
E2 4.7 kb deletion may be a founder mutation and pre-
served in other Austronesian aboriginal tribes of Taiwan.
The main aspects to the treatment of MSUD are long-
term management and the treatment of episodes of acute
metabolic decompensation and frequent infections.1,3,4
Treatment consists of ongoing dietary adjustments that
match nutritional intake, judicious supplementation with
isoleucine and valine, and frequent clinical and biochem-
ical monitoring such as indices of zinc sufficiency.2Conflicts of interest
The author declares no conflicts of interest.References
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